<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958125</url>
  </required_header>
  <id_info>
    <org_study_id>GC-003</org_study_id>
    <nct_id>NCT01958125</nct_id>
  </id_info>
  <brief_title>A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.</brief_title>
  <official_title>A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElectroCore INC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElectroCore INC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will look at a non-invasive treatment for people suffering with chronic and
      episodic headaches. Study subjects will be randomized to an active treatment or an in-active
      treatment for 2 weeks. After the 2 weeks all subjects will continue to treat with an active
      treatment for an additional 2 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective double blind, randomized, sham-controlled, multi-center
      investigation designed for comparison of two parallel groups, GammaCore® (active treatment)
      and a sham, (in-active) treatment. The study period begins with a 1-week run-in period,
      followed by a 2 week comparative period when the subjects are randomized (1:1) to either
      active treatment or sham (in-active) treatment. The comparative period will be followed by an
      open label 2 week period, where the subjects in the sham treatment group will switch in
      treatment assignment and receive an active treatment and the active group will continue to
      receive an active treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>Headache pain was collected at the beginning of the attack (all treated attacks) and 15 minutes post treatment pain free attacks.
Data was collected in the patient diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disability From Baseline (Randomization) to 2 Weeks After Baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>Mean difference of scores on a 5 step disability scale. Disability was measured at baseline and after the randomization phase (2 weeks later). Lowest score is 1 and is better than the higher score at 5 that is the worst. An increase, higher scores, means worsening.
minor
minor/moderate
moderate
moderate/severe
severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Questionnaire EQ-5D-3L (Euroqol- 5D-3L) From Baseline to After 2 Weeks Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>EQ-5D-3L descriptive system comprises 5 dimensions: mobility, self-care, activity, pain and anxiety. Each dimension has 3 levels: 1 = no problems, 2 = moderate problems, 3=extreme problems. Subjects indicate health state by ticking choosing appropriate statement in each dimension and a VAS scale (Overall health) from 0-100 mm where higher score is better (100) than lower score (0).
Patients completed the EQ-5D-3L at baseline (the start of the randomized period and at 2 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Used Any Type of Rescue Medication</measure>
    <time_frame>2 weeks</time_frame>
    <description>Following treatment at 15 minutes, patients recorded use of any rescue medication(s) in the diary'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the Headache Pain Free Attack Rates at 30 Minutes Following the Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>The headache pain was collected at the beginning of the attack and 30 minutes post treatment in the patient diary.
The number of pain free (no pain) attacks are compared to all attacks treated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>gammacore</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gammacore active device to be used noninvasively to the vagal nerve in the neck.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inactive gammacore</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>same as the active treatment, but without the therapy treatment provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gammaCore</intervention_name>
    <description>Vagal stimulation</description>
    <arm_group_label>gammacore</arm_group_label>
    <arm_group_label>inactive gammacore</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is 18 years or older

          -  Has been diagnosed with episodic or chronic cluster headache in accordance with the
             ICHD-2 Classification criteria (2ndEd)

          -  Is capable of completing the 5-point pain scale, disability scale and other
             self-assessments

          -  Agrees to refrain from starting new medication aimed to control the cluster headache
             for the duration of the run-in and randomized phase

          -  Is able to provide written Informed Consent

        Exclusion Criteria:1.

          -  Episodic cluster headache sufferers who are not in a cluster headache bout at the time
             of screening and enrollment

          -  2. Need to commence treatment with oral or injectable steroids for eventual
             concomitant medical conditions

          -  3. Has a lesion (including lymphadenopathy), dysaesthesia, previous surgery or
             abnormal anatomy at the GammaCore® treatment site

          -  4. Is currently taking medication for indications other than CH that in the opinion of
             the clinician may interfere with the study

          -  5. Has a history of any cranial aneurysm, intracranial haemorrhage, brain tumours or
             significant head trauma

          -  6. Diagnosed or suspected secondary headache

          -  7. Has other significant pain problem that might confound the study assessments in the
             opinion of the investigator

          -  8. Has known or suspected severe atherosclerotic cardiovascular disease, severe
             carotid artery disease (e.g. bruits or history of transient ischemic attack (TIA) or
             cerebral vascular accident CVA), congestive heart failure (CHF), known severe coronary
             artery disease or recent (5 years) myocardial infarction

          -  9. Has an abnormal baseline ECG (e.g. second and third degree heart block, atrial
             fibrillation, atrial flutter, recent history of ventricular tachycardia or ventricular
             fibrillation, or clinically significant premature ventricular contraction)

          -  10. Has had a previous, cervical vagotomy

          -  11. Has uncontrolled high blood pressure

          -  12. Is currently implanted with an electrical and/or neurostimulator device, including
             but not limited to cardiac pacemaker or defibrillator, vagal neurostimulator, deep
             brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant

          -  13. Has a history of carotid endarterectomy or vascular neck surgery

          -  14. Has been implanted with metal cervical spine hardware or has a metallic implant
             near the GammaCore stimulation site

          -  15. Has a recent (12 months) or repeated history of syncope

          -  16. Has a recent (12 months) or repeated history of seizure

          -  17. Has a known history or suspicion of substance abuse or addiction, or overuse of
             acute headache medication

          -  18. Has psychiatric or cognitive disorder and/or behavioural problems which in the
             opinion of the clinician may interfere with the study

          -  19. Is pregnant, nursing, thinking of becoming pregnant in the next 6 weeks 20. Is
             participating in any other therapeutic clinical investigation or has participated in a
             clinical trial in the preceding 30 days

          -  21. Is a relative of or an employee of the investigator or the clinical study site
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Goadsbury, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital, Dept for Neurology and Clinical Neurosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glostrup Hospital, Danish Headache Centre</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westdeutches Kopfschmerzzentrum</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kopfschmerzklinik Königstein</name>
      <address>
        <city>Königstein im Taunus</city>
        <zip>D-61462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern, University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center, Neurology Department, K5-Q-104</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary, Neurology Department</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free, Dept for Neurology and Clinical Neurosciences</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Southern Hospital, Neurology Department</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Center, Neurology Department</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
  </removed_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/29231763</url>
    <description>Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study.</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <results_first_submitted>February 28, 2018</results_first_submitted>
  <results_first_submitted_qc>February 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vagus nerve stimulation</keyword>
  <keyword>vagal nerve stimulation</keyword>
  <keyword>nVNS</keyword>
  <keyword>VNS</keyword>
  <keyword>cluster headache</keyword>
  <keyword>non invasive</keyword>
  <keyword>gammacore</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The study is publlished and no other IPD data will be shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>gammaCore</title>
          <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
        </group>
        <group group_id="P2">
          <title>Sham Device</title>
          <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Missing diary data</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No headache attacks</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>gammaCore</title>
          <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
        </group>
        <group group_id="B2">
          <title>Sham Device</title>
          <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="10.60"/>
                    <measurement group_id="B2" value="46.9" spread="10.63"/>
                    <measurement group_id="B3" value="45.4" spread="10.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment</title>
        <description>Headache pain was collected at the beginning of the attack (all treated attacks) and 15 minutes post treatment pain free attacks.
Data was collected in the patient diary.</description>
        <time_frame>2 weeks</time_frame>
        <population>ITT-Intention To Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore</title>
            <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment</title>
          <description>Headache pain was collected at the beginning of the attack (all treated attacks) and 15 minutes post treatment pain free attacks.
Data was collected in the patient diary.</description>
          <population>ITT-Intention To Treat population</population>
          <units>Number of attacks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of treated attacks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of treated attack pain free at 15 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disability From Baseline (Randomization) to 2 Weeks After Baseline</title>
        <description>Mean difference of scores on a 5 step disability scale. Disability was measured at baseline and after the randomization phase (2 weeks later). Lowest score is 1 and is better than the higher score at 5 that is the worst. An increase, higher scores, means worsening.
minor
minor/moderate
moderate
moderate/severe
severe</description>
        <time_frame>2 weeks</time_frame>
        <population>Safety population, three patients in the Sham device group have no data</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore</title>
            <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disability From Baseline (Randomization) to 2 Weeks After Baseline</title>
          <description>Mean difference of scores on a 5 step disability scale. Disability was measured at baseline and after the randomization phase (2 weeks later). Lowest score is 1 and is better than the higher score at 5 that is the worst. An increase, higher scores, means worsening.
minor
minor/moderate
moderate
moderate/severe
severe</description>
          <population>Safety population, three patients in the Sham device group have no data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Disability score at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0.2"/>
                    <measurement group_id="O2" value="3.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disability score at 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="0.2"/>
                    <measurement group_id="O2" value="3.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change of Questionnaire EQ-5D-3L (Euroqol- 5D-3L) From Baseline to After 2 Weeks Treatment</title>
        <description>EQ-5D-3L descriptive system comprises 5 dimensions: mobility, self-care, activity, pain and anxiety. Each dimension has 3 levels: 1 = no problems, 2 = moderate problems, 3=extreme problems. Subjects indicate health state by ticking choosing appropriate statement in each dimension and a VAS scale (Overall health) from 0-100 mm where higher score is better (100) than lower score (0).
Patients completed the EQ-5D-3L at baseline (the start of the randomized period and at 2 weeks).</description>
        <time_frame>2 weeks</time_frame>
        <population>Safety population, three patients in the Sham group had no data for EQ-5D-3L</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore</title>
            <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Questionnaire EQ-5D-3L (Euroqol- 5D-3L) From Baseline to After 2 Weeks Treatment</title>
          <description>EQ-5D-3L descriptive system comprises 5 dimensions: mobility, self-care, activity, pain and anxiety. Each dimension has 3 levels: 1 = no problems, 2 = moderate problems, 3=extreme problems. Subjects indicate health state by ticking choosing appropriate statement in each dimension and a VAS scale (Overall health) from 0-100 mm where higher score is better (100) than lower score (0).
Patients completed the EQ-5D-3L at baseline (the start of the randomized period and at 2 weeks).</description>
          <population>Safety population, three patients in the Sham group had no data for EQ-5D-3L</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.1"/>
                    <measurement group_id="O2" value="1.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mobility after 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.1"/>
                    <measurement group_id="O2" value="1.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Selfcare at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0"/>
                    <measurement group_id="O2" value="1.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Selfcare after 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0"/>
                    <measurement group_id="O2" value="1.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.1"/>
                    <measurement group_id="O2" value="1.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activity after 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.1"/>
                    <measurement group_id="O2" value="1.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.1"/>
                    <measurement group_id="O2" value="1.9" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain after 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.1"/>
                    <measurement group_id="O2" value="1.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.1"/>
                    <measurement group_id="O2" value="1.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety after 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.1"/>
                    <measurement group_id="O2" value="1.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS scale at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="2.5"/>
                    <measurement group_id="O2" value="63.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VAS scale after 2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.4" spread="2.5"/>
                    <measurement group_id="O2" value="66.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Used Any Type of Rescue Medication</title>
        <description>Following treatment at 15 minutes, patients recorded use of any rescue medication(s) in the diary'</description>
        <time_frame>2 weeks</time_frame>
        <population>ITT-Intention To Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore</title>
            <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Used Any Type of Rescue Medication</title>
          <description>Following treatment at 15 minutes, patients recorded use of any rescue medication(s) in the diary'</description>
          <population>ITT-Intention To Treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparison of the Headache Pain Free Attack Rates at 30 Minutes Following the Treatment</title>
        <description>The headache pain was collected at the beginning of the attack and 30 minutes post treatment in the patient diary.
The number of pain free (no pain) attacks are compared to all attacks treated</description>
        <time_frame>2 weeks</time_frame>
        <population>ITT-Intention To Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>gammaCore</title>
            <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
          </group>
          <group group_id="O2">
            <title>Sham Device</title>
            <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Headache Pain Free Attack Rates at 30 Minutes Following the Treatment</title>
          <description>The headache pain was collected at the beginning of the attack and 30 minutes post treatment in the patient diary.
The number of pain free (no pain) attacks are compared to all attacks treated</description>
          <population>ITT-Intention To Treat population</population>
          <units>Number of attacks</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of attacks treated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of attacks treated and pain free at 30 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>diaries and open questions</desc>
      <group_list>
        <group group_id="E1">
          <title>gammaCore</title>
          <description>Active Comparator: gammacore gammacore active device to be used noninvasively to the vagal nerve in the neck</description>
        </group>
        <group group_id="E2">
          <title>Sham Device</title>
          <description>Placebo Comparator: inactive gammacore same as the active treatment, but without the therapy treatment provided</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Left lower pain abdominal</sub_title>
                <description>Abdominal pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed and anxious</sub_title>
                <description>Patient experienced more anxiety and depression after starting treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MeDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lowe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Application site paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Application site vesicles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myokymia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Typical aura without headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Piloerection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin sensitisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director Clinical Affairs</name_or_title>
      <organization>electroCore Inc.</organization>
      <phone>+1 973 355 6683</phone>
      <email>clinical@electrocorellc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

